According to a post on the FDA’s website, Juno Therapeutics, a Bristol-Myers Squibb company, received orphan designation for its treatment of nodal marginal zone lymphoma, lisocabtagene maraleucel. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BMY:
- Bristol-Myers announces three-year follow-up results from CheckMate-816 study
- Zevra Therapeutics appoints Dixon to board of directors
- Bristol-Myers announces european approval of Sotyktu
- Evotec, Bristol-Myers expand strategic neurodegeneration partnership
- BridgeBio announces first patient dosed in Phase 1 trial of BBP-398 with OPDIVO